YATHARTH · NSE
Yatharth Hospital & Trauma Care Services Limited
₹1,139.5
+6.26% (+₹67.1)
Prev. close
₹1,072.4
Volume
64,84,052
Delivery %
14.3%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Yatharth Hospital & Trauma Care Services Limited
Yatharth Hospital & Trauma Care Services Limited, together with its subsidiaries, owns and operates super-specialty hospitals in India. The company offers services in the areas of medicine, cardiology, neurosciences, general surgery, nephrology and urology, pediatrics, gastroenterology, pulmonology, gynecology, orthopedics, spine and rheumatology, plastic and cosmetic surgery, ear, nose, throat, endocrinology, critical care, dermatology, nuclear medicine, and cancer and bone marrow transplant. It also provides services in the areas of GI surgery and liver transplant, robotic surgery, kidney transplant, IVF and fertility, emergency medicine, ophthalmology, dentistry, psychology and psychiatry, physiotherapy and rehabilitation, anesthesiology, radiology, pathology and laboratory medicine, nutrition and health, interventional spine and pain medicine, neurology, neurosurgery, and cardiovascular and thoracic surgery. In addition, the company sells medicines and canteen food. The company was incorporated in 2008 and is based in Noida, India.
Details
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Mr. Amit Kumar Singh
Headquarters
Noida
Employees
7,440
Website
yatharthhospitals.comExchange
View on NSE ↗Key stats
Market cap
₹10,979.58 Cr
P/E ratio (TTM)
55.6
Dividend yield
0.09%
EPS (TTM)
₹20.48
Beta (1Y · daily vs NIFTY 50)
0.84
Beta (5Y · monthly vs NIFTY 50)
1.17
Shares float
4.15 Cr
EPS · quarter ended Jun 2026
₹4.88
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹520.29 Cr | ₹670.55 Cr | ₹880.49 Cr | ₹1,207.17 Cr | |
| EBITDA | — | ₹136.57 Cr | ₹195.55 Cr | ₹236.42 Cr | ₹317.90 Cr |
| — | ₹65.77 Cr | ₹114.48 Cr | ₹130.55 Cr | ₹175.38 Cr | |
| Diluted EPS | — | ₹7.66 | ₹14.46 | ₹14.72 | ₹18.2 |
Revenue, Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Net income, Pretax income, Tax provision, Interest expense, Other income, Diluted EPS have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ₹426.02 Cr | ₹485.97 Cr | ₹1,019.33 Cr | ₹1,731.18 Cr | ₹2,281.53 Cr | |
| ₹263.77 Cr | ₹267.41 Cr | ₹84.65 Cr | ₹11.59 Cr | ₹264.09 Cr | |
| Stockholders' equity | ₹116.89 Cr | ₹182.96 Cr | ₹874.32 Cr | ₹1,605.46 Cr | ₹1,780.56 Cr |
CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹63.78 Cr | ₹-3.08 Cr | ₹131.17 Cr | ₹204.52 Cr | |
| Investing cash flow | — | ₹-20.31 Cr | ₹-225.87 Cr | ₹-387.58 Cr | ₹-598.03 Cr |
| — | ₹-17.75 Cr | ₹304.21 Cr | ₹509.09 Cr | ₹253.53 Cr | |
| Capital expenditure | — | ₹-19.81 Cr | ₹-93.37 Cr | ₹-301.93 Cr | ₹-316.54 Cr |
| End cash position | — | ₹37.43 Cr | ₹112.70 Cr | ₹360.22 Cr | ₹220.24 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Aug 23–Sep 23(2Q) | Dec 23 | Mar 24–Sep 24(3Q) | Dec 24 | Mar 25–Sep 25(3Q) | Dec 25–Jun 26(3Q) |
|---|---|---|---|---|---|---|
| Promoter | 66.33% | 66.44% | 66.54% | 61.44% | 61.64% | 55.80% |
| Public | 33.67% | 33.56% | 33.46% | 38.56% | 38.36% | 44.20% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Yatharth Hospital & Trauma Care Services Limited | ₹9,460.07 Cr | ₹966.3 | 52.4 | 5.31 | 9.8% | 0.15 | +35.9% | +20.5% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Concall transcripts
Show all 13
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
12 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.